Altrubio Inc.
Clinical trials sponsored by Altrubio Inc., explained in plain language.
-
New hope for Tough-to-Treat ulcerative colitis: experimental drug ALTB-268 under study
Disease control OngoingThis study tests an experimental drug called ALTB-268 in 50 adults with moderate-to-severe ulcerative colitis that did not improve with biologic therapies. The goal is to see if the drug can reduce disease activity, measured by symptoms like stool frequency and rectal bleeding, o…
Phase: PHASE2 • Sponsor: AltruBio Inc. • Aim: Disease control
Last updated May 19, 2026 11:46 UTC
-
New ulcerative colitis drug candidate begins first human tests
Knowledge-focused OngoingThis early-phase study tests the safety and tolerability of a single dose of ALTB-268 given intravenously to 24 healthy adults. The goal is to see how the body handles the drug and identify any side effects before moving to patient studies. This is a first step toward developing …
Phase: PHASE1 • Sponsor: AltruBio Inc. • Aim: Knowledge-focused
Last updated May 26, 2026 08:35 UTC